Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Bazedoxifene for the prevention of postmenopausal osteoporosis

Authors Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti

Published 5 December 2008 Volume 2008:4(6) Pages 1229—1242

DOI https://doi.org/10.2147/TCRM.S3476

Review by Single-blind

Peer reviewer comments 3

Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti

Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte 53100-Siena, Italy

Abstract: Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and without stimulating the uterus or the breast. In both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine profile and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter capacity has led to the development of a novel class of menopausal therapy called tissue selective estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus, without aggravating menopausal vasomotor symptoms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear to confirm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to raloxifene, coupled with efficacy on menopausal vasomotor symptoms not achieved by SERM alone. These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders.

Keywords: bazedoxifene, SERM, estrogen, postmenopausal osteoporosis, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Lasofoxifene: Evidence of its therapeutic value in osteoporosis

Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Ranuccio Nuti

Core Evidence 2009, 4:113-129

Published Date: 1 July 2009

Readers of this article also read:

Clinical neurorestorative progress in traumatic brain injury

Huang H, Chen L, Huang H

Journal of Neurorestoratology 2015, 3:57-62

Published Date: 20 March 2015

Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses

Xie Z, Qu Y, Leng Y, Sun W, Ma S, Wei J, Hu J, Zhang X

Drug Design, Development and Therapy 2015, 9:1679-1689

Published Date: 18 March 2015

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

Cogollo E, Silva MA, Isenberg D

Drug Design, Development and Therapy 2015, 9:1331-1339

Published Date: 5 March 2015

Perindopril for improving cardiovascular events

DiNicolantonio JJ, O’Keefe JH

Vascular Health and Risk Management 2014, 10:539-548

Published Date: 30 August 2014

Mixed dyslipidemias in primary care patients in France

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E

Vascular Health and Risk Management 2012, 8:247-254

Published Date: 19 April 2012

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

Early cardiovascular abnormalities in newly diagnosed obstructive sleep apnea

Jean-Philippe Baguet, Marie Nadra, Gilles Barone-Rochette, et al

Vascular Health and Risk Management 2009, 5:1063-1073

Published Date: 11 December 2009

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

Serge Halimi, Anja Schweizer, Biljana Minic, James Foley, Sylvie Dejager

Vascular Health and Risk Management 2008, 4:481-492

Published Date: 6 June 2008